SiSaf

SiSaf is a private, clinical-stage biotech leveraging its unique Bio-Courier® delivery platform to advance a pipeline of RNA therapeutics. Its lead program, a siRNA therapy for Osteopetrosis Type II (ADO2), has secured FDA Orphan Drug and Rare Pediatric Disease designations and is progressing toward an IND. The company's technology differentiates itself from standard LNPs by enabling room-temperature storage and separate manufacturing of the carrier and payload, potentially simplifying logistics and expanding therapeutic applications. SiSaf is funded through venture capital and strategic partnerships.

Bio-Courier® technology: A hybrid drug delivery platform combining a bioabsorbable silicon matrix with lipids and amino acids to create stabilized nanoparticles for RNA delivery. It enables room-temperature storage and separate manufacturing of carrier and payload.

SiSaf competes in the RNA delivery space against dominant LNP technologies (used by Moderna, Pfizer/BioNTech) and other nanoparticle/formulation companies. Its differentiation lies in its hybrid silicon-lipid structure, which aims to improve stability and logistics. For its therapeutic programs, it competes with other gene-silencing and targeted oncology therapies.